The earliest expected NDA filing with the FDA is Q4 2026, which would put a realistic FDA decision in 2027 or later
While findings suggest diverse biological activities, these remain under investigation and are not confirmed for practical applications
Other psychological risks include impulsive behavior, anxiety, depression, and paranoia
Augoustides-Savvopoulou P, Luka Z, Karyda S, Stabler SP, Allen RH, Patsiaoura K, Wagner C, Mudd SH (2003) Glycine N-methyltransferase deficiency: a new patient with a novel mutation
Liposomal Glutathione contains 450mg reduced l-glutathione per teaspoon
C Biotin 5000 mcg v 10000 mcg u l liu lng cao v thng c s dng cho cc mc ch c th